# QT prolongation on cancer medicines: ECG and blood salt monitoring, and when to pause or stop

Source: https://onco.cc/protocols/qt-prolongation-monitoring-on-anticancer-drugs/  
OnCo record `qt-prolongation-monitoring-on-anticancer-drugs` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Some cancer medicines slow the heart's electrical reset between beats, seen on a heart tracing (ECG) as a long QT interval. Rarely this sets off a dangerous rhythm. Your team should do an ECG and check your blood salts before you start, review your other medicines, and repeat the ECG on a schedule. Get medical help straight away if you faint, feel dizzy or your heartbeat is fast or irregular.

## Summary

Before a QT-prolonging cancer medicine, record a 12-lead ECG with the QT interval corrected by the Fridericia formula (ESMO 2020 [I, A] for a baseline ECG; ESC 2022 recommends Fridericia), correct potassium, magnesium and calcium, and review every other medicine for QT-prolonging drugs and, for ribociclib, quizartinib and revumenib, strong CYP3A inhibitors. The ESC algorithm asks for potassium above 4.0 mmol/L and magnesium above 1.10 mmol/L, and for cardio-oncology evaluation before starting if QTcF is above 480 ms. The labels are stricter: ribociclib is started only below 450 ms, and quizartinib and revumenib are not started above 450 ms.

Repeat ECGs follow the product's label: ribociclib at about day 14 of the first cycle; quizartinib weekly during induction and consolidation and for at least the first month of maintenance; revumenib at least weekly for 4 weeks and then at least monthly; osimertinib and adagrasib in people at risk. ESC recommends QTc monitoring at baseline and at 14 and 28 days for everyone on ribociclib (Class I, Level A), and an ECG after any dose increase of a QT-prolonging medicine (Class I, Level C).

The action thresholds are QTcF above 480 ms and 500 ms. ESC: weekly ECGs for people without symptoms at 480 to 500 ms (Class I, Level C); at 500 ms or more, interrupt the medicine and repeat the ECG every 24 hours until it resolves (Class I, Level C), withdraw any other offending drug and correct electrolytes and other risk factors (Class I, Level C). ESC and IC-OS both say that a rise of more than 60 ms from baseline should not routinely change treatment while QTc stays below 500 ms. Labels are stricter in places: ribociclib and revumenib are interrupted above 480 ms, and adagrasib and revumenib are withheld for a rise of more than 60 ms. ESC recommends stopping the medicine after torsades de pointes or a sustained ventricular tachyarrhythmia (Class I, Level C), and every label read stops it permanently for torsades de pointes or signs of serious or life-threatening arrhythmia. Restarting after significant prolongation needs a multidisciplinary discussion first (Class I, Level C); ESC says it may be considered, ideally at a reduced dose (Class IIb, Level C), with weekly ECGs for the first 4 to 6 weeks and then monthly (Class I, Level C). Quizartinib carries a boxed warning and in the United States is supplied only through a restricted programme. This page explains care; the treating team's own protocol and the product's current label come first.

## Fields

- Kind: Protocol
- Last checked: 2026-11-17
- Also known as: QTc monitoring; long QT on cancer treatment; ECG before ribociclib; ECG monitoring on quizartinib; QTcF; Fridericia correction; torsades de pointes; drug-induced long QT; heart tracing on cancer tablets
- Tags: protocol; cardio-oncology; side-effect-management

## Connected records

- technologies: [Cardio-oncology](https://onco.cc/technologies/cardio-oncology/)
- protocols: [Drug, herbal and food interaction review for anticancer treatment](https://onco.cc/protocols/anticancer-drug-interaction-review/), [Heart risk assessment and monitoring before, during and after heart-toxic cancer treatment](https://onco.cc/protocols/cardio-oncology-risk-assessment-and-cardiac-surveillance/), [High blood pressure and protein in the urine on VEGF-pathway inhibitors: monitoring, treatment and when to pause the cancer medicine](https://onco.cc/protocols/hypertension-and-proteinuria-on-vegf-pathway-inhibitors/), [Low magnesium on cetuximab and panitumumab: monitoring and replacement](https://onco.cc/protocols/hypomagnesaemia-on-egfr-antibodies/), [Low potassium and low phosphate on anticancer drugs: monitoring, replacement and dose holds](https://onco.cc/protocols/low-potassium-and-low-phosphate-on-anticancer-drugs/)
- key papers: [2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)](https://onco.cc/key-papers/paper-lyon-eur-heart-j/)
- fronts: [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- drugs: [Adagrasib](https://onco.cc/drugs/adagrasib/), [Arsenic trioxide](https://onco.cc/drugs/arsenic-trioxide/), [Glasdegib](https://onco.cc/drugs/glasdegib/), [Ivosidenib](https://onco.cc/drugs/ivosidenib/), [Midostaurin](https://onco.cc/drugs/midostaurin/), [Nilotinib](https://onco.cc/drugs/nilotinib/), [Osimertinib](https://onco.cc/drugs/osimertinib/), [Pazopanib](https://onco.cc/drugs/pazopanib/), [Quizartinib](https://onco.cc/drugs/quizartinib/), [Revumenib](https://onco.cc/drugs/revumenib/), [Ribociclib](https://onco.cc/drugs/ribociclib/), [Selpercatinib](https://onco.cc/drugs/selpercatinib/), [Sunitinib](https://onco.cc/drugs/sunitinib/), [Toremifene](https://onco.cc/drugs/toremifene/), [Vandetanib](https://onco.cc/drugs/vandetanib/)
- institutions: [European Society for Medical Oncology (ESMO)](https://onco.cc/institutions/esmo/)
- terms: [Cardiotoxicity (LVEF decline, cardiomyopathy)](https://onco.cc/terms/cardiotoxicity/), [QT prolongation](https://onco.cc/terms/qt-prolongation/)

---
JSON: https://onco.cc/api/v1/entities/qt-prolongation-monitoring-on-anticancer-drugs.json